Allos Therapeutics Announces Closing of Public Offering
14 10월 2009 - 5:05AM
Business Wire
Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced the
closing of its previously announced underwritten public offering of
14,000,000 shares of newly issued common stock at a public offering
price of $7.10 per share. The Company received net proceeds from
the sale of the shares, after underwriting discounts, commissions
and estimated offering expenses, of approximately $93.0 million.
Allos has also granted the underwriters a 30-day option to purchase
up to an aggregate of 2,100,000 additional shares of common stock
to cover over-allotments, if any. Allos currently anticipates using
the net proceeds of the offering primarily for activities relating
to the commercialization of FOLOTYN™ (pralatrexate injection),
preclinical research and clinical development of FOLOTYN, and for
general corporate purposes.
J.P. Morgan Securities Inc. and Citigroup Global Markets Inc.
acted as joint book-running managers of the offering. Leerink Swann
LLC acted as co-lead manager of the offering. JMP Securities LLC,
Needham & Company, LLC, and RBC Capital Markets acted as
co-managers of the offering. A copy of the final prospectus
supplement and accompanying prospectus relating to the offering may
be obtained by contacting J.P. Morgan Securities Inc., Attention:
Prospectus Department, 4 Chase Metrotech Center, CS Level,
Brooklyn, NY 11245 or by calling (718) 242-8002 or Citigroup Global
Markets Inc., Prospectus Department, Brooklyn Army Terminal, 140
58th Street, 8th Floor, Brooklyn, NY 11220, (800) 831-9146.
The shares were issued pursuant to a shelf registration
statement that was declared effective by the Securities and
Exchange Commission on August 28, 2009. This press release does not
and shall not constitute an offer to sell or the solicitation of an
offer to buy Allos’ common stock, nor shall there be any sale of
the common stock in any state or jurisdiction in which such an
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any state.
About Allos Therapeutics
Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics.
Safe Harbor Statement
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements include statements concerning the amount and anticipated
use of the net proceeds of the offering, and other statements which
are other than statements of historical facts. In some cases, you
can identify forward-looking statements by terminology such as
"may," "will," "should," "expects," "intends," "plans,"
anticipates," "believes," "estimates," "predicts," "projects,"
"potential," "continue," and other similar terminology or the
negative of these terms, but their absence does not mean that a
particular statement is not forward-looking. Such forward-looking
statements are not guarantees of future performance and are subject
to risks and uncertainties that may cause actual results to differ
materially from those anticipated by the forward-looking
statements. These risks and uncertainties include, among others:
the risk that additional capital may be required in the future to
continue the Company’s development and commercialization plans.
Additional information concerning these and other factors that may
cause actual results to differ materially from those anticipated in
the forward-looking statements is contained in the "Risk Factors"
section of the Company's Quarterly Report on Form 10-Q for the
quarter ended June 30, 2009, and in the Company's other periodic
reports and filings with the Securities and Exchange Commission and
the prospectus supplement related to the offering. The Company
cautions investors not to place undue reliance on the
forward-looking statements contained in this press release. All
forward-looking statements are based on information currently
available to the Company on the date hereof, and the Company
undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of
this presentation, except as required by law.
Note: Allos Therapeutics, Inc., the Allos Therapeutics, Inc.
logo, FOLOTYN, the FOLOTYN logo and all other Allos names are
trademarks of Allos Therapeutics, Inc. in the United States and in
other selected countries.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024